[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370553-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370553-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","research-hotspots-and-frontier-analysis-of-the-novel-immune-checkpoint-nectin-4","Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4","","Nectin-4 is established as a therapeutic target for antibody-drug conjugates (ADCs), especially in advanced urothelial carcinoma. While many studies address Nectin-4, no work has systematically examined hotspots, cutting-edge directions, and tissue expression using combined bibliometric analysis and bioinformatics. Results show rising attention to Nectin-4 in cancer immunotherapy and ADC development, with urothelial carcinoma as the core focus and breast and bladder cancers increasing. Key priorities include improving ADC safety and managing cutaneous adverse events, and dual targeting with TROP-2 for next-generation ADCs. These findings support Nectin-4 as a biomarker bridging research areas while balancing efficacy and toxicity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/research-hotspots-and-frontier-analysis-of-the-novel-immune-checkpoint-nectin-4/370553/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/research-hotspots-and-frontier-analysis-of-the-novel-immune-checkpoint-nectin-4/370553.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is Nectin-4 considered a key target for ADC research?","Question",{"text":63,"@type":64},"Nectin-4 is an immunoglobulin-like transmembrane protein involved in cell adhesion, proliferation, migration, and angiogenesis, and it is highly expressed across multiple tumor types. It has become a major ADC target, supported by clinical relevance in urothelial carcinoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What approach does the study use to identify research hotspots and frontiers?",{"text":68,"@type":64},"The study applies bibliometric analysis combined with bioinformatics to map research trends. It examines publication patterns and related biological expression considerations to reveal hotspots and cutting-edge directions.",{"name":70,"@type":61,"acceptedAnswer":71},"What future research priorities does the study emphasize?",{"text":72,"@type":64},"Priorities include optimizing ADC safety profiles, particularly managing cutaneous adverse events. The study also highlights dual targeting strategies combining Nectin-4 with TROP-2 as promising for next-generation ADC therapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370553,1790242191,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":113,"preview_page_count":33,"preview_urls":146},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","RESEARCH ARTICLE     \nResearch hotspots and frontier analysis of the novel immune checkpoint Nectin-4  \nYu Qiaoa, Wanyu Zhaob, Yusen Gouc,d,e, Yuwei Lif, Fang Sua, Rui Wanga, Jiejun Wanga, Haibo Zhanga, Lei Sunc,d,e, Feng Qianc,d,e, and Zishu Wang a  \naDepartment of Medical Oncology, First Affiliated Hospital of Bengbu Medical University, Bengbu Medical University, Bengbu, China; bDepartment of Biochemistry and Molecular Biology, School of Laboratory Medicine, and Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui, China; cShanghai Frontiers Science Center of Drug Target Identification and Delivery, Shanghai Jiao Tong University, Shanghai, China; dEngineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, China; e National Key Laboratory of Innovative Immunotherapy, Shanghai Jiao Tong University, Shanghai, China; fGraduate School, Wenzhou Medical University, Wenzhou, Zhejiang, China  \nABSTRACT  \nNectin-4 has emerged as a pivotal therapeutic target for antibody-drug conjugates (ADCs), particularly in advanced urothelial carcinoma (aUC) research. Although extensive literature has been reported on Nectin-4, it is worth noting that no studies have yet systematically investigated the hotspots, cutting-edge directions, and tissue expression of this target using a combination of bibliometric analysis and bioinformatics methods. Findings reveal growing interest in Nectin-4‘s role in cancer immunotherapy and ADC development. Urothelial carcinoma remains the primary focus, with breast and bladder cancers gaining traction. Key research priorities include optimizing ADC safety profiles, particularly managing cutaneous adverse events. Notably, dual targeting strategies combining Nectin-4 with TROP-2 show promise for next-generation ADC therapies. The study highlights evolving clinical needs, from target validation to treatment optimization, positioning Nectin-4 as a versatile biomarker bridging multiple cancer research domains. These insights emphasize the protein’s translational potential while underscoring the importance of balancing therapeutic efficacy with toxicity management in ADC development.  \nARTICLE HISTORY  \nReceived 8 February 2025 Revised 25 April 2025 Accepted 8 May 2025  \nKEYWORDS  \nNectin-4; CiteSpace; VOSviewer; research hotspots; Frontiers  \nIntroduction  \nNECTIN4, also called Poliovirus Receptor-Related Protein 4 (PVRL4), is a transmembrane protein part of the Nectins family of immunoglobulin-like molecules. 1 NECTIN4 is important for cell adhesion, cell proliferation, cell migration, and the creation of blood vessels. It promotes angiogenesis by interacting with integrin β4, activating the Src, PI3K, Akt, and inducible nitric oxide synthase (iNOS) signaling pathways.2 In addition, NECTIN4 is highly expressed in various tumor types, including breast cancer,3 lung cancer,4 urothelial carcinoma,5 colorectal cancer, pancreatic cancer, and ovarian cancer. Its high expression is closely associated with tumor initiation, progression, and prognosis.  \nAntibiotic-drug conjugates (ADCs) targeting NECTIN4 have become a research hotspot.6 Enfortumabvedotin (brand name: Padcev®) is the first FDA-approved ADC targeting NECTIN4 to treat urothelial carcinoma.6 This drug binds to NECTIN4 on the surface of tumor cells, undergoes endocytosis, releases cytotoxic agents, inhibits cell division, and induces apoptosis.7 Other NECTIN4-targeted drugs under investigation include ETx-22,8 developed by Emergence Therapeutics, and 9MW2821 by Mewi Biologics.9 These drugs have demonstrated good antitumor activity and tolerability in preclinical and clinical studies.  \nNumerous reviews have summarized NECTIN-4 from multiple perspectives. For instance, Kaiyue Li elucidated its  \nmolecular mechanisms in oncogenesis, diagnostic potential, and therapeutic value as a target fo","cbCaigyoLomVDl0z","https://ap.wps.com/l/cbCaigyoLomVDl0z","pdf",10204686,12,"English","# Abstract\n# Introduction\n## Nectin-4 biology and tumor relevance\n## NECTIN4-targeted ADCs as a research hotspot\n## Existing reviews and remaining research gaps\n## Study aim and bibliometric methodology","[{\"question\":\"Why is Nectin-4 considered a key target for ADC research?\",\"answer\":\"Nectin-4 is an immunoglobulin-like transmembrane protein involved in cell adhesion, proliferation, migration, and angiogenesis, and it is highly expressed across multiple tumor types. It has become a major ADC target, supported by clinical relevance in urothelial carcinoma.\"},{\"question\":\"What approach does the study use to identify research hotspots and frontiers?\",\"answer\":\"The study applies bibliometric analysis combined with bioinformatics to map research trends. It examines publication patterns and related biological expression considerations to reveal hotspots and cutting-edge directions.\"},{\"question\":\"What future research priorities does the study emphasize?\",\"answer\":\"Priorities include optimizing ADC safety profiles, particularly managing cutaneous adverse events. The study also highlights dual targeting strategies combining Nectin-4 with TROP-2 as promising for next-generation ADC therapies.\"}]","Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4 | PDF",1790189097,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67f87dc2198c5c985f861693d243a8ca.webp",983,1280,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92c80dee1f7c400d1b4361a0583ff1fe.webp",982,1278,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97c983e0a68ba436ef9e64a3ec3b587e.webp",981,1277,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec781deced3ea55b0d6756b4cd656aa7.webp",980,1276]